Engineered immune cells take on Hard-to-Treat blood cancer
NCT ID NCT07477912
First seen Mar 23, 2026 · Last updated May 26, 2026 · Updated 10 times
Summary
This study tests a new treatment called anti-BCMA CAR-T cell therapy for adults with multiple myeloma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified in a lab to better find and attack cancer cells. The goal is to see if it is safe and how well it controls the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
State Institution Minsk Scientific and Practical Center for Surgery, Transplantology, and Hematology
RECRUITINGMinsk, 220087, Belarus
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.